Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:14633668rdf:typepubmed:Citationlld:pubmed
pubmed-article:14633668lifeskim:mentionsumls-concept:C0017296lld:lifeskim
pubmed-article:14633668lifeskim:mentionsumls-concept:C0150369lld:lifeskim
pubmed-article:14633668lifeskim:mentionsumls-concept:C0034721lld:lifeskim
pubmed-article:14633668lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:14633668lifeskim:mentionsumls-concept:C0017638lld:lifeskim
pubmed-article:14633668lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:14633668lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:14633668lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:14633668lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:14633668lifeskim:mentionsumls-concept:C0024485lld:lifeskim
pubmed-article:14633668lifeskim:mentionsumls-concept:C1979874lld:lifeskim
pubmed-article:14633668lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:14633668lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:14633668pubmed:issue22lld:pubmed
pubmed-article:14633668pubmed:dateCreated2003-11-24lld:pubmed
pubmed-article:14633668pubmed:abstractTextMagnetic resonance imaging relaxation times, T(1rho) and Carr-Purcell T(2) (CP-T(2)), were measured in a glioma herpes simplex virus-thymidine kinase gene therapy model. In treated tumors with >50% cell death by histology, T(1rho) and CP-T(2) measured with short spacing (tau(CP)) between centers of adiabatic refocusing pulses showed similar enhanced sensitivity to cytotoxic cell damage over CP-T(2) measured with long tau(CP) (long-tau(CP) T(2): 54.3 +/- 0.7 and 55.4 +/- 1.2 ms, P = 0.30; short-tau(CP) T(2): 61.3 +/- 1.0 and 64.2 +/- 1.1 ms, P < 0.05 before and day 2 of treatment, respectively). Without treatment, long-tau(CP) T(2) provided the most pronounced contrast between tumor and normal cerebral tissue. These data demonstrate that endogenous T(2) contrast can be modulated and extended in a manner likely to be clinically important.lld:pubmed
pubmed-article:14633668pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14633668pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14633668pubmed:languageenglld:pubmed
pubmed-article:14633668pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14633668pubmed:citationSubsetIMlld:pubmed
pubmed-article:14633668pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14633668pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14633668pubmed:statusMEDLINElld:pubmed
pubmed-article:14633668pubmed:monthNovlld:pubmed
pubmed-article:14633668pubmed:issn0008-5472lld:pubmed
pubmed-article:14633668pubmed:authorpubmed-author:Ylä-Herttuala...lld:pubmed
pubmed-article:14633668pubmed:authorpubmed-author:GarwoodMichae...lld:pubmed
pubmed-article:14633668pubmed:authorpubmed-author:KauppinenRist...lld:pubmed
pubmed-article:14633668pubmed:authorpubmed-author:KettunenMikko...lld:pubmed
pubmed-article:14633668pubmed:authorpubmed-author:GröhnOlli H...lld:pubmed
pubmed-article:14633668pubmed:authorpubmed-author:LehtimäkiKimm...lld:pubmed
pubmed-article:14633668pubmed:authorpubmed-author:ValonenPiia...lld:pubmed
pubmed-article:14633668pubmed:authorpubmed-author:VäisänenTuula...lld:pubmed
pubmed-article:14633668pubmed:issnTypePrintlld:pubmed
pubmed-article:14633668pubmed:day15lld:pubmed
pubmed-article:14633668pubmed:volume63lld:pubmed
pubmed-article:14633668pubmed:ownerNLMlld:pubmed
pubmed-article:14633668pubmed:authorsCompleteYlld:pubmed
pubmed-article:14633668pubmed:pagination7571-4lld:pubmed
pubmed-article:14633668pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:14633668pubmed:meshHeadingpubmed-meshheading:14633668...lld:pubmed
pubmed-article:14633668pubmed:meshHeadingpubmed-meshheading:14633668...lld:pubmed
pubmed-article:14633668pubmed:meshHeadingpubmed-meshheading:14633668...lld:pubmed
pubmed-article:14633668pubmed:meshHeadingpubmed-meshheading:14633668...lld:pubmed
pubmed-article:14633668pubmed:meshHeadingpubmed-meshheading:14633668...lld:pubmed
pubmed-article:14633668pubmed:meshHeadingpubmed-meshheading:14633668...lld:pubmed
pubmed-article:14633668pubmed:meshHeadingpubmed-meshheading:14633668...lld:pubmed
pubmed-article:14633668pubmed:meshHeadingpubmed-meshheading:14633668...lld:pubmed
pubmed-article:14633668pubmed:meshHeadingpubmed-meshheading:14633668...lld:pubmed
pubmed-article:14633668pubmed:meshHeadingpubmed-meshheading:14633668...lld:pubmed
pubmed-article:14633668pubmed:meshHeadingpubmed-meshheading:14633668...lld:pubmed
pubmed-article:14633668pubmed:meshHeadingpubmed-meshheading:14633668...lld:pubmed
pubmed-article:14633668pubmed:meshHeadingpubmed-meshheading:14633668...lld:pubmed
pubmed-article:14633668pubmed:year2003lld:pubmed
pubmed-article:14633668pubmed:articleTitleNovel magnetic resonance imaging contrasts for monitoring response to gene therapy in rat glioma.lld:pubmed
pubmed-article:14633668pubmed:affiliationDepartment of Biomedical NMR and National Bio NMR Facility, A. I. Virtanen Institute for Molecular Sciences, University of Kuopio, PO Box 1627, FIN-70211 Kuopio, Finland. grohn@messi.uku.filld:pubmed
pubmed-article:14633668pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:14633668pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:14633668pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14633668lld:pubmed